The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Reflecting a strategic portfolio rebalancing among major institutional holders, Savant Capital LLC has significantly reduced its exposure to the consumer and healthcare sectors. According to reports, the firm slashed its position in PepsiCo by 48.7% and sold 4,488 shares of Amgen, marking a 15.7% reduction in its stake. This partial exit occurred despite PepsiCo reporting quarterly earnings of $1.61 per share, which surpassed market expectations.
Sign in to access this content
Sign InThese moves coincide with mixed performance among industry peers; for instance, Coca-Cola reported organic revenue growth of 11% in its latest quarter per market data, while Amgen faces intensifying competition in the biopharmaceutical space. According to search data, other institutional funds have maintained their positions in consumer staples to capitalize on dividend growth, suggesting Savant Capital's decision may be driven by profit-taking rather than a fundamental sector shift.
Traders should monitor PEP, which closed at $172.40, and AMGN at $312.15 (close May 29, 2026). Looking ahead at the economic calendar, the upcoming CB Consumer Confidence data will be a key catalyst for sentiment in large-cap equities. Technical support levels for PepsiCo remain in focus near its May lows based on pre-fetched price data, as investors weigh institutional selling against solid corporate fundamentals.